Diclofenac API Manufacturers & Suppliers

Diclofenac is used to manage pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute musculoskeletal injuries. It is also employed for post‑traumatic or post‑surgical pain and may be combined with misoprostol in patients at higher risk of NSAID‑related gastric ulceration. Its effects derive from COX‑1 and COX‑2 inhibition, which reduces prostaglandin‑mediated inflammatory and nociceptive signaling.

Diclofenac belongs to the following therapeutic categories: Acetic Acid Derivatives and Related Substances, Acids, Carbocyclic, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.

The primary indications for Diclofenac: Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma, It is often used in combination with [misoprostol] as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.

Diclofenac inhibits cyclooxygenase-1 and -2, the enzymes responsible for production of prostaglandin (PG) G₂ which is the precursor to other PGs.[label,T116] These molecules have broad activity in pain and inflammation and the inhibition of their production is the common mechanism linking each effect of Diclofenac. PGE₂ is the primary PG involved in modulation of nociception.It mediates peripheral sensitization through a variety of effects.PGE₂ activates the G_q-coupled EP₁ receptor leading to increased activity of the inositol trisphosphate/phospholipase C pathway. Activation of this pathway releases intracellular stores of calcium which directly reduces action potential threshold and activates protein kinase C (PKC) which contributes to several indirect mechanisms. PGE₂ also activates the EP₄ receptor, coupled to G_s, which activates the adenylyl cyclase/protein kinase A (AC/PKA) signaling pathway. PKA and PKC both contribute to the potentiation of transient receptor potential cation channel subfamily V member 1 (TRPV1) potentiation, which increases sensitivity to heat stimuli. They also activate tetrodotoxin-resistant sodium channels and inhibit inward potassium currents. PKA further contributes to the activation of the P2X3 purine receptor and sensitization of T-type calcium channels. The activation and sensitization of depolarizing ion channels and inhibition of inward potassium currents serve to reduce the intensity of stimulus necessary to generate action potentials in nociceptive sensory afferents. PGE₂ act via EP₃ to increase sensitivity to bradykinin and via EP₂ to further increase heat sensitivity. Central sensitization occurs in the dorsal horn of the spinal cord and is mediated by the EP₂ receptor which couples to G_s. Pre-synaptically, this receptor increases the release of pro-nociceptive neurotransmitters glutamate, CGRP, and substance P. Post-synaptically it increases the activity of AMPA and NMDA receptors and produces inhibition of inhibitory glycinergic neurons. Together these lead to a reduced threshold of activating, allowing low intensity stimuli to generate pain signals. PGI₂ is known to play a role via its G_s-coupled IP receptor although the magnitude of its contribution varies. It has been proposed to be of greater importance in painful inflammatory conditions such as arthritis. By limiting sensitization, both peripheral and central, via these pathways NSAIDs can effectively reduce inflammatory pain. PGI₂ and PGE₂ contribute to acute inflammation via their IP and EP₂ receptors.Similarly to β adrenergic receptors these are G_s-coupled and mediate vasodilation through the AC/PKA pathway. PGE₂ also contributes by increasing leukocyte adhesion to the endothelium and attracts the cells to the site of injury.PGD₂ plays a role in the activation of endothelial cell release of cytokines through its DP₁ receptor.PGI₂ and PGE₂ modulate T-helper cell activation and differentiation through IP, EP₂, and EP₄ receptors which is believed to be an important activity in the pathology of arthritic conditions. By limiting the production of these PGs at the site of injury, NSAIDs can reduce inflammation. PGE₂ can cross the blood-brain barrier and act on excitatory G_q EP₃ receptors on thermoregulatory neurons in the hypothalamus.This activation triggers an increase in heat-generation and a reduction in heat-loss to produce a fever. NSAIDs prevent the generation of PGE₂ thereby reducing the activity of these neurons.

Diclofenac has a dose‑dependent risk of gastrointestinal irritation, ulceration, and bleeding due to reduced mucosal prostaglandin production. It can also cause renal impairment, hypertension, fluid retention, and hypersensitivity reactions, with rare reports of hepatotoxicity and photosensitivity. Overexposure to the API may lead to CNS depression, nausea, vomiting, epigastric pain, or bleeding, and in uncommon severe cases acute renal failure or coma. Manufacturing settings require containment measures to limit inhalation or accidental ingestion because significant GI and systemic toxicities can occur at elevated exposures.

Diclofenac’s low aqueous solubility and gastric‑irritant potential drive the use of enteric or delayed‑release coatings in oral products to protect the drug and minimize local irritation. Parenteral formulations require solubilizers and careful pH control to maintain solution clarity and prevent precipitation. For topical, transdermal, and ophthalmic products, its lipophilicity supports local delivery, and handling typically focuses on protecting the API from light and oxidation.

Diclofenac is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.

Oral Diclofenac is a lipophilic, poorly water‑soluble molecule, so formulations often rely on enteric or delayed‑release coatings to maintain stability in the acidic gastric environment and to manage dissolution. These coatings also help limit gastric irritation. The primary stability considerations for oral products relate to maintaining the integrity of these coatings and ensuring consistent dissolution rather than sensitivity to light or oxidation.